Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Neurogene reported positive interim data from its Phase 1/2 trial of NGN-401, showing all eight pediatric participants gained developmental milestones across core domains of Rett syndrome with durable improvements lasting up to 24 months. - The company has dosed multiple participants in its Embolden registrational trial in Q4 2025 and expects to complete dosing in Q2 2026, with interim data from both pediatric and adolescent/adult cohorts planned for mid-2026. - NGN-401 at the 1E15 vg dose continues to demonstrate a favorable safety profile with no evidence of hemophagocytic lymphohistiocytosis (HLH), positioning the therapy as a potential best-in-class treatment for Rett syndrome.
- The FDA has placed a clinical hold on Rocket Pharmaceuticals' Phase II gene therapy trial for RP-A501 after a patient developed capillary leak syndrome and subsequently died. - The patient experienced serious complications including fluid leaking from blood vessels into surrounding tissues, causing swelling and low blood pressure, followed by an acute systemic infection. - Rocket is investigating whether a novel immune suppression agent recently added to the pre-treatment regimen may have contributed to the adverse event. - The company's stock tumbled 63% in premarket trading, and analysts estimate the clinical hold could take weeks to months to resolve.
• A newly released global clinical trials review provides extensive data on Interstitial Cystitis research, tracking trial numbers and enrollment trends across major countries worldwide. • The report categorizes trials by region, phase, status, and sponsorship, highlighting key pharmaceutical companies including Astellas Pharma, AbbVie, Johnson & Johnson, and Pfizer as prominent sponsors. • This comprehensive analysis serves as a strategic resource for stakeholders making investment decisions in IC research, offering insights into trial success rates and identifying optimal locations for clinical studies.
- Neurogene has developed a monitoring and treatment algorithm designed to reverse hemophagocytic lymphohistiocytosis (HLH), a rare hyperinflammatory syndrome linked to high-dose AAV gene therapy. - The protocol focuses on daily monitoring of the "three Fs" - elevated ferritin levels, fever, and falling blood counts - with high-dose corticosteroids as first-line treatment and anakinra as second-line therapy. - Despite using a lower dose (E13 vg/kg range) in its Phase 1/2 trial of NGN-401 for Rett syndrome, Neurogene has incorporated this protocol as a precautionary measure, as HLH has not been reported at this dose level.
- A comprehensive 2025 pipeline analysis identifies over 20 companies developing more than 20 therapeutic candidates for Rett syndrome, highlighting significant industry investment in this rare neurological disorder. - Anavex Life Sciences leads with blarcamesine in Phase III trials, representing the most advanced treatment targeting SIGMA1 and muscarinic receptors to restore cellular homeostasis. - Gene therapy approaches dominate the pipeline with TSHA-102 and NGN-401 delivering MECP2 gene replacement using AAV9 vectors in Phase I/II trials. - The therapeutic landscape spans multiple modalities including small molecules, gene therapies, and biologics, addressing the critical unmet medical need in Rett syndrome treatment.
• Neurogene has suspended enrollment in the high-dose arm of its NGN-401 gene therapy trial for Rett syndrome after a patient developed life-threatening systemic hyperinflammatory syndrome, a known risk with AAV vector therapies. • Despite early efficacy signals showing "meaningful gains of skills and developmental milestones" in low-dose patients, the company's shares plummeted nearly 44% following the safety concerns announcement. • The trial will continue with the low-dose cohort, though with delayed enrollment timeline, as the company works to balance promising efficacy data against serious safety considerations for this devastating neurological disorder.
• The FDA's START program, designed to expedite rare disease therapy development, has chosen its first candidates for enhanced guidance and support. • Denali Therapeutics' DNL12 for mucopolysaccharidosis IIIA, Neurogene's NGN-401 for Rett syndrome, and Larimar Therapeutics' nomlabofusp for Friedreich's ataxia are among the selected therapies. • Grace Science's GS-100 gene therapy for NGLY1 deficiency is also included, marking a significant step forward in addressing this life-threatening condition with no approved treatments. • The START program aims to provide comprehensive support in clinical trial design and data generation, facilitating efficient development of potentially life-saving therapies.
- Novartis reports positive Phase 3 results for intrathecal onasemnogene abeparvovec (OAV101 IT) in spinal muscular atrophy (SMA) type 2 patients, showing promise in those aged 2-18. - India's first gene therapy for severe hemophilia-A demonstrates success with zero bleeding rate in initial trial, offering new hope for patients with this serious bleeding disorder. - Researchers develop a novel CRISPR-based delivery system for prenatal gene editing, aiming to treat genetic problems at very early stages of development.
• AbbVie's Vyalev, a 24-hour subcutaneous levodopa infusion, gained FDA approval for managing motor fluctuations in advanced Parkinson's, offering a novel therapeutic approach. • Intellia's CRISPR therapy, NTLA-2001, demonstrated safe redosing in ATTR amyloidosis patients, achieving additive pharmacodynamic effects on the target protein. • A phase 3 study revealed that buntanetap is a safe and well-tolerated drug which improves motor, nonmotor, and cognitive symptoms of Parkinson's disease. • The FDA supported using αSyn-SAA biomarker in Parkinson's clinical trials, enhancing therapeutic development through improved diagnostic precision.
• Two companies, Neurogene and Taysha Gene Therapies, are in Phase 1/2 clinical trials with gene therapies targeting the MECP2 gene for Rett syndrome. • These therapies aim to address the underlying genetic cause of Rett syndrome, unlike existing treatments that only manage symptoms. • Both companies have incorporated regulatory mechanisms to ensure precise MECP2 expression, avoiding complications from overexpression. • Preliminary data from ongoing trials are expected in late 2024 and early 2025, offering hope for a potential disease-modifying treatment.
